Advertisement
RLAY vs XNCR
Which Stock Would AI Choose? Relay Therapeutics (RLAY) vs. Xencor (XNCR) Stock Comparison
Key Takeaways
- Relay Therapeutics (RLAY) and Xencor (XNCR) are both clinical-stage biotech firms, but they operate with fundamentally different drug discovery platforms and therapeutic focuses.
- RLAY leverages a computational dynamics-based platform integrating AI, physics, and structural biology, while XNCR specializes in protein engineering with its XmAb bispecific antibody technology.
- Both stocks have faced significant downward pressure in recent months amid a challenging biotech funding environment and broader sector rotation away from speculative growth names.
- Cash runway remains a critical metric for both companies, with each reporting enough capital to fund operations into 2026–2027 based on recent filings.
- Differentiated pipelines and partnership revenues give XNCR a modestly more diversified revenue base, while RLAY's more concentrated pipeline presents both higher risk and potentially higher reward.
- AI-driven trading analysis suggests a nuanced picture, with neither stock currently exhibiting strong bullish momentum in the prevailing market conditions.
Introduction
Comparing RLAY and XNCR offers investors a window into two distinct approaches to next-generation drug discovery. Both companies sit at the intersection of biotechnology and computational innovation, yet their scientific platforms, partnership strategies, and pipeline priorities diverge in meaningful ways. For traders and investors assessing the biotech landscape — particularly those drawn to platform-based companies with multi-asset potential — understanding how these two names stack up can help clarify the risk-reward calculus. This comparison examines their recent market performance, business fundamentals, and relative positioning in an environment that has been notably unforgiving to early-stage biotech firms.
RLAY Overview and Recent Performance
RLAY, or Relay Therapeutics, is a clinical-stage precision medicine company built around its Dynamo platform, which integrates computational chemistry, structural biology, and machine learning to model protein motion and design targeted therapies. The company's lead programs focus on oncology and genetic diseases, with its PI3Kα inhibitor (RLY-2608) and FGFR2 inhibitor (lirafugratinib) representing the most advanced clinical assets.
In recent weeks, RLAY shares have traded near multi-year lows, reflecting a combination of sector-wide pressure on pre-revenue biotech names and company-specific pipeline scrutiny. The broader market's reduced appetite for risk has weighed heavily on clinical-stage companies that lack near-term commercial catalysts. Despite presenting updated clinical data at medical conferences in recent months, the stock has struggled to sustain any positive momentum. Cash reserves, while sufficient to fund operations into the second half of 2026 according to recent quarterly filings, remain a focal point for investors evaluating dilution risk. Trading volumes have been moderate, and institutional ownership patterns suggest cautious positioning rather than conviction buying.
XNCR Overview and Recent Performance
XNCR, or Xencor Inc., is a clinical-stage biotechnology company focused on engineered monoclonal antibodies and bispecific antibody programs built on its proprietary XmAb technology platform. The company's pipeline spans oncology, autoimmune disease, and immunology, with multiple partnered programs generating milestone and royalty revenue. Key assets include plamotamab, vudalimab, and several partnered programs with major pharmaceutical companies such as Janssen, Novartis, and Amgen.
XNCR shares have similarly experienced sustained downward pressure in recent months, with the stock trading substantially below its three-year highs. While the company benefits from a more diversified revenue stream thanks to its partnership agreements — which provide periodic milestone payments and research funding — this has not insulated XNCR from the prevailing risk-off sentiment in biotech. Recent pipeline updates, including data readouts from early and mid-stage trials, have been met with muted market reactions. Cash and equivalents, reported to fund operations into 2027, offer a somewhat extended runway relative to some peers, though investors continue to monitor spending levels closely given the capital-intensive nature of antibody engineering and clinical development.
Trending AI Robots
In an environment where human analysis must contend with rapidly shifting market conditions, many traders are augmenting their research with AI-driven tools. Tickeron's Trending AI Robots page offers a curated selection of AI trading bots from a broader pool of hundreds that trade thousands of different tickers. These bots are algorithmically selected based on their real-time alignment with current market regimes. The bots featured in this section employ varied trading styles — from swing trading and trend following to pattern recognition and momentum strategies — across different timeframes and ticker universes. Some bots in the marketplace have generated historically impressive annualized returns, with statistical metrics such as Sharpe ratios and win rates available for traders to evaluate. Each bot's performance statistics, trade history, and strategy logic are transparently displayed, helping users identify approaches that match their risk tolerance. Explore the Trending AI Robots to discover which automated strategies are currently capturing opportunities in sectors including biotechnology.
Head-to-Head Comparison
When evaluating RLAY and XNCR side by side, several differentiating factors emerge. From a business model perspective, XNCR's partnership-heavy strategy provides a degree of revenue diversification and validation from large pharmaceutical collaborators, whereas RLAY remains more reliant on internally funded pipeline advancement, creating a tighter link between stock performance and clinical catalysts. On growth drivers, RLAY's near-term trajectory hinges heavily on proof-of-concept data from RLY-2608 and lirafugratinib, while XNCR's is spread across a broader set of partnered and wholly owned programs.
In terms of recent momentum, neither stock has demonstrated sustained positive price action, though XNCR's partnership revenues have historically provided a modest buffer during periods of pipeline uncertainty. Risk factors for both include clinical trial binary risk, potential dilution, and dependence on favorable capital market conditions. However, XNCR's broader pipeline and multiple partnerships arguably reduce single-asset risk relative to RLAY's more concentrated portfolio. Sector exposure is similar — both are mid-cap biotech names sensitive to interest rate expectations and sector rotation dynamics. Market sentiment around both tickers has been cautious, with short interest levels reflecting skepticism about near-term catalysts in the current macro environment.
Tickeron AI Verdict
Based on an analysis of observable factors — including trend consistency, partnership revenue stability, pipeline breadth, and cash runway duration — Tickeron's AI analysis would likely express a relative preference for XNCR in the current environment. XNCR's more diversified revenue base through pharmaceutical partnerships, extended cash runway into 2027, and broader pipeline reduce single-event binary risk relative to RLAY. That said, the AI's assessment would emphasize that neither stock currently exhibits strong bullish momentum as measured by trend strength indicators, and both remain vulnerable to sector-wide headwinds. The relative edge for XNCR reflects a probabilistic evaluation of risk-adjusted positioning rather than a definitive fundamental superiority. Market conditions, clinical data outcomes, and macroeconomic shifts could rapidly alter this calculus.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLAY is a Hold and XNCR is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RLAY’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).
- RLAY’s FA Score: 1 green, 4 red.
- XNCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RLAY’s TA Score shows that 3 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).
- RLAY’s TA Score: 3 bullish, 4 bearish.
- XNCR’s TA Score: 4 bullish, 5 bearish.
Price Growth
RLAY (@Biotechnology) experienced а +6.18% price change this week, while XNCR (@Biotechnology) price change was +11.24% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.82%. For the same industry, the average monthly price growth was -3.57%, and the average quarterly price growth was +3059.28%.
Reported Earning Dates
RLAY is expected to report earnings on Nov 11, 2026.
XNCR is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+2.82% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| RLAY | XNCR | RLAY / XNCR | |
| Capitalization | 4.37B | 1.61B | 272% |
| EBITDA | -293.61M | -131.66M | 223% |
| Gain YTD | 135.697 | 40.954 | 331% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 10.7M | 97.4M | 11% |
| Total Cash | 642M | 445M | 144% |
| Total Debt | 31.6M | 175M | 18% |
RLAY | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 34 | 35 | |
P/E GROWTH RATING 1..100 | 10 | 6 | |
SEASONALITY SCORE 1..100 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RLAY's Valuation (77) in the null industry is in the same range as XNCR (89) in the Biotechnology industry. This means that RLAY’s stock grew similarly to XNCR’s over the last 12 months.
RLAY's Profit vs Risk Rating (100) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that RLAY’s stock grew similarly to XNCR’s over the last 12 months.
XNCR's SMR Rating (98) in the Biotechnology industry is in the same range as RLAY (99) in the null industry. This means that XNCR’s stock grew similarly to RLAY’s over the last 12 months.
RLAY's Price Growth Rating (34) in the null industry is in the same range as XNCR (35) in the Biotechnology industry. This means that RLAY’s stock grew similarly to XNCR’s over the last 12 months.
XNCR's P/E Growth Rating (6) in the Biotechnology industry is in the same range as RLAY (10) in the null industry. This means that XNCR’s stock grew similarly to RLAY’s over the last 12 months.
| RLAY | XNCR | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 83% | 5 days ago 90% |
| Stochastic ODDS (%) | 5 days ago 80% | 5 days ago 77% |
| Momentum ODDS (%) | 5 days ago 84% | 5 days ago 70% |
| MACD ODDS (%) | 5 days ago 86% | 5 days ago 90% |
| TrendWeek ODDS (%) | 5 days ago 83% | 5 days ago 78% |
| TrendMonth ODDS (%) | 5 days ago 82% | 5 days ago 73% |
| Advances ODDS (%) | 5 days ago 86% | 5 days ago 75% |
| Declines ODDS (%) | 9 days ago 87% | 9 days ago 81% |
| BollingerBands ODDS (%) | N/A | 5 days ago 76% |
| Aroon ODDS (%) | 5 days ago 88% | 5 days ago 77% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NYM | 24.89 | 0.02 | +0.08% |
| AB New York Intermediate Municipal ETF | |||
| USMF | 53.85 | 0.01 | +0.01% |
| WisdomTree US Multifactor | |||
| IJUN | 32.02 | N/A | N/A |
| Innovator Intl Dev Pwr Bffr ETF - Jun | |||
| RJVI | 24.84 | -0.06 | -0.24% |
| RJ Eagle Vertical Income ETF | |||
| BNDS | 50.07 | -0.16 | -0.32% |
| Infrastructure Capital Bond Income ETF | |||
RLAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with KURA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then KURA could also see price increases.
| Ticker / NAME | Correlation To RLAY | 1D Price Change % | ||
|---|---|---|---|---|
| RLAY | 100% | +0.86% | ||
| KURA - RLAY | 50% Loosely correlated | +2.93% | ||
| IMNM - RLAY | 44% Loosely correlated | +2.64% | ||
| XNCR - RLAY | 44% Loosely correlated | +3.70% | ||
| VCYT - RLAY | 44% Loosely correlated | -2.01% | ||
| CGEM - RLAY | 44% Loosely correlated | +3.10% | ||
More | ||||